Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples